Bighat Biosciences Raises $75 Million In Series B Funding To Design Safer, More Effective Antibodies
Bighat Biosciences Raises $75 Million In Series B Funding To Design Safer, More Effective Antibodies
07/20/22, 12:09 PM
Location
san mateoMoney raised
$75 million
Industry
biotechnology
Round Type
series b
BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round, led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, among others. The investment brings BigHat’s total funding to date to $100 million. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round, which will be used to scale the capacity of MillinerTM, an integrated AI/ML- wet lab platform, advance therapeutic programs toward human clinical trials, aggressively hire drug discovery and development talent and to accelerate strategic collaborations with flagship partners.
Company Info
Location
1900 alameda de las pulgas
san mateo, california, united states
Additional Info
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.